Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,232 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COPD (Chronic Obstructive Pulmonary Disease) Clear all
Completed No phase listed Observational

Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs

NCT04628039
View directory record Official record
Conditions
COVID-19, Chronic Lung Diseases
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 6, 2026, 3:41 AM EDT
Completed No phase listed Observational

Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices

NCT01430936
View directory record Official record
Conditions
Cardiac Decompensation
Interventions
Not listed
Lead sponsor
Aventyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Mineola, New York • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

NCT00571428
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol Tartrate Inhalation Solution, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Medford, Oregon • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01085045
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 6, 2026, 3:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Use of CTC in NSCLC

NCT01990651
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Effect of BIBW 2948 BS in COPD

NCT00423137
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Not applicable Interventional

Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder

NCT00752531
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Home Automated Telemanagement (HAT)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

NCT00297102
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Fullerton, California • Los Angeles, California • Palmdale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 6, 2026, 3:41 AM EDT
Not listed No phase listed Observational

Perry Virtual - A Prospective and Observational Rural Health Trial

NCT04483154
View directory record Official record
Conditions
COPD, Arrhythmia, Murmur, Heart, Chronic Disease
Interventions
Coala Heart Monitor
Device
Lead sponsor
Coala Life, Inc
Industry
Eligibility
65 Years and older
Enrollment
100 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Linden, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT02772159
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770
View directory record Official record
Conditions
COPD
Interventions
Advair 250, Placebo- matched, Placebo, Advair 250 - matched
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05037929
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

Study in Patients With COPD

NCT00215423
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
5 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
7
States / cities
Phoenix, Arizona • Wheat Ridge, Colorado • Hines, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01867762
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
JNJ 49095397, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • St Louis, Missouri • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

NCT01209104
View directory record Official record
Conditions
Nutritional Status
Interventions
GSK1325756
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Not applicable Interventional

Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease

NCT00601055
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Depression
Interventions
Problem Solving-Rx Adherence (PSA), PID-C
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 6, 2026, 3:41 AM EDT
Terminated Phase 3 Interventional Results available

Pulmonary Rehabilitation Before Lung Cancer Resection

NCT02887521
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
education, rehabilitation, pedometer, surgery
Other · Procedure · Device
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

NCT05165485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
76
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease

NCT01448850
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MEDI8968 600 mg IV, 300 mg SC, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
45 Years to 75 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Peoria, Arizona • Clearwater, Florida • Duluth, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 6, 2026, 3:41 AM EDT
Not listed No phase listed Observational

Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)

NCT01074515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
4
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 6, 2026, 3:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Obstructive Pulmonary Disorder and Acute Exercise

NCT02780219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 6, 2026, 3:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients

NCT00472264
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PET imaging
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 6, 2026, 3:41 AM EDT
Not listed Early Phase 1 Interventional

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 6, 2026, 3:41 AM EDT